Evidence map›Paper›PMID 38629295›Full record

ArticleCancer medicine2024

Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.

Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Tadashi NishimuraDepartment of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.ORCID 0000-0002-1688-1602
Hajime FujimotoDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Takumi FujiwaraDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Kentaro ItoRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.
Atsushi FujiwaraDepartment of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.
Hisamichi YudaDepartment of Pulmonary Medicine, Kuwana City Medical Center, Kuwana, Japan.
Hidetoshi ItaniDepartment of Respiratory Medicine, Ise Red Cross Hospital, Ise, Japan.
Masahiro NaitoDepartment of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
Shuji KodamaDepartment of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.
Kazuki FuruhashiDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Akihiko YagiDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Haruko SaikiDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Taro YasumaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Tomohito OkanoDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Atsushi TomaruDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Motoaki TanigawaDepartment of Respiratory Medicine, Ise Red Cross Hospital, Ise, Japan.
Masamichi YoshidaDepartment of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.
Osamu HatajiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.
Hidenori IbataDepartment of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
Corina N D'Alessandro-GabazzaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Esteban C GabazzaDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.ORCID 0000-0001-5748-1499
Tetsu KobayashiDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
Mie University · JPMie Chuo Medical Center · JPIse Red Cross Hospital · JPSoka Municipal Hospital · JPSunagawa City Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence prognosis in non-small cell lung cancer patients, few studies have investigated the prognostic value of immune-related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune-related adverse events after first-line treatment with immune checkpoint inhibitor-based chemotherapy for extensive-stage small cell lung cancer.

methodsWe enrolled 90 patients with extensive-stage small cell lung cancer who received immune checkpoint inhibitor-based chemotherapy as first-line treatment from September 2019 to December 2022 in six hospitals in Japan. The patients were categorized into groups with and without immune-related adverse events.

resultsThere were 23 patients with and 67 without immune-related adverse events. Seventeen patients had grade 1-2 immune-related adverse events, and nine (including overlapping cases) had grade ≥3. The most frequent immune-related adverse event was a skin rash. The median survival time was 22 months in patients with immune-related adverse events and 9.3 months in patients without immune-related adverse events. The hazard ratio was 0.40 (95% confidence interval: 0.19-0.83, p = 0.013).

conclusionsThe results of this study show that immune-related adverse events are associated with improved survival outcomes in patients with extensive-stage small cell lung cancer.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaHumansImmune Checkpoint InhibitorsPrognosisRetrospective StudiesImmune Checkpoint Inhibitorsimmune checkpoint inhibitorimmune‐related adverse eventssmall cell lung cancer

Identifiers

PMID38629295
PMCPMC11022147
OpenAlexW4394872924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.